"Angelman Syndrome Antisense Treatment" in Patent Application Approval Process (USPTO 20230332152).

Keywords: Angelman Syndrome; Antisense Technology; Bioengineering; Biotechnology; Central Nervous System; Central Nervous System Diseases and Conditions; Chromosome Disorders; Congenital Abnormalities; Enzymes and Coenzymes; Genetics; Health and Medicine; Movement Disorders; Musculoskeletal Diseases and Conditions; Nuclease; Patent Application EN Angelman Syndrome Antisense Technology Bioengineering Biotechnology Central Nervous System Central Nervous System Diseases and Conditions Chromosome Disorders Congenital Abnormalities Enzymes and Coenzymes Genetics Health and Medicine Movement Disorders Musculoskeletal Diseases and Conditions Nuclease Patent Application 170 170 1 11/06/23 20231110 NES 231110 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventor Dindot, Scott Victor (College Station, TX, US), filed on June 30, 2023, was made available online on October 19, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The modified oligonucleotide of claim 14, wherein the modified oligonucleotide is a nuclease guide RNA oligonucleotide (gRNA)." A modified oligonucleotide comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length with nucleic acid complementarity to a contiguous portion of the nucleotide sequence set forth in SEQ ID NO: 2. The modified oligonucleotide of claim 14, wherein the modified oligonucleotide is a short hairpin RNA oligonucleotide (shRNA). [Extracted from the article]